Synedgen Announces the Launch of Moisyn Rinse to Treat Dry Mouth
CLAREMONT, Calif. – October 10, 2018 – Synedgen, a company leveraging its proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory conditions, today announced the market launch of Moisyn™ Rinse for the treatment of the symptoms of xerostomia, or dry mouth. Moisyn Rinse is being distributed by Prisyna, the oral care division of Synedgen.
The Moisyn product line is the first glycomics targeted therapy that has been shown in a clinical study to reduce pain and increase comfort for patients living with dry mouth1. Moisyn products, including Moisyn Mist, the convenient spray formulation, provide advanced relief from the symptoms of dry mouth while moisturizing and lubricating the oral cavity.
“The introduction of Moisyn Rinse is part of Synedgen’s commitment to improving oral health based on the benefits of our glycomics technology,” said Shenda Baker, Ph.D., President and Chief Operating Officer of Synedgen. “The Synedent® and Moisyn family of products demonstrate the value that glycomics can bring to addressing important unmet patient needs. We are bringing that same commitment to addressing other inflammatory and infectious diseases associated with the mucosal interface utilizing the promise of glycomics to improve human health.”
“The commercial launch of Moisyn Rinse is another milestone for Prisyna and our dedicated team,” said Leo Pranitis, General Manager of Prisyna. “Moisyn provides relief for the symptoms of dry mouth, a condition which is associated with tooth decay, disturbed sleep, oral infections and a range of other oral health problems. The glycomicstechnology that differentiates both our Moisyn and Synedent family of products is unique, truly innovative and most importantly, addresses a need that is not currently being fully met by the product offerings on the market.”
About Xerostomia (Dry Mouth)
Xerostomia, or dry mouth, causes dryness in the oral cavity, most commonly the tongue and roof of the mouth. Typically, it is identified by a reduction or absence of oral saliva and can be brought on by a variety of conditions, including aging. Over 1000 prescription and non-prescription medications, including drugs for treating anxiety, depression, high blood pressure, allergies, and cancer are known to alter the production of saliva and cause dry mouth as a side effect.
Common problems stemming from dry mouth include tooth decay, disturbed sleep, dry throat, burning sensation in the throat, gum disease, oral infections, taste change, and difficulty speaking and swallowing.
Synedgen is developing a new class of health care products based on glycomics, a revolutionary approach using glycopolymers to target mucosal and dermal interfaces. Synedgen uses its Glycomics Technology Platform (GTP) to discover and develop ultra-purified glycopolymers that enhance and mimic the innate immune system by targeting the cell surface glycocalyx and mucosal surfaces. Synedgen has successfully leveraged the GTP to develop marketed Prisyna oral care and Synedgen wound care products, as well as SNSP113, which has been licensed to Synspira and is currently in clinical development for the treatment of cystic fibrosis. Synedgen has established research and manufacturing facilities in Claremont, California.https://www.synedgen.com/
Prisyna, the oral healthcare division of Synedgen, is developing and commercializing a new class of oral health care products based on glycomics, a revolutionary approach using natural glycopolymers to target the mucosal interface. Prisyna uses this unique technology to develop oral health care products that clean the mouth, reduce pain and irritation on sensitive mucosal surfaces and improve overall oral health. Prisyna is building a family of environmentally safe products using cutting edge science to promote healthy teeth, gums and oral surfaces. http://www.prisyna.com/
1Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jan;123(1):76-83. doi: 10.1016/j.oooo.2016.09.008. Epub 2016 Sep 28.